(Q33401986)

26 July 2017

title

Phase 2 study of everolimus monotherapy in patients with nonfunctioning neuroendocrine tumors or pheochromocytomas/paragangliomas (English)

1 reference

26 July 2017

1 reference

Hyo Jin Lee

7

0 references

Yung-Jue Bang

9

object named as

Yung-Jue Bang

1 reference

26 July 2017

Do-Youn Oh

1

1 reference

26 July 2017

Tae-Won Kim

2

1 reference

26 July 2017

Young Suk Park

3

1 reference

26 July 2017

Sang Joon Shin

4

1 reference

26 July 2017

Seong Hoon Shin

5

1 reference

26 July 2017

Eun-Kee Song

6

1 reference

26 July 2017

Kewn-Wook Lee

8

1 reference

26 July 2017

language of work or name

English

0 references

publication date

26 June 2012

1 reference

26 July 2017

1 reference

26 July 2017

volume

118

1 reference

26 July 2017

issue

24

1 reference

26 July 2017

page(s)

6162-6170

1 reference

One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States

26 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27675

Neuroendocrine tumor epidemiology: contrasting Norway and North America.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27675

A three-decade analysis of 3,911 small intestinal neuroendocrine tumors: the rapid pace of no progress

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27675

Biological characteristics and treatment outcomes of metastatic or recurrent neuroendocrine tumors: tumor grade and metastatic site are important for treatment strategy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27675

Liver metastases of neuroendocrine carcinomas: interventional treatment via transarterial embolization, chemoembolization and thermal ablation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27675

Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27675

Phase II study of pemetrexed in patients with advanced neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27675

A Phase II trial of gemcitabine for metastatic neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27675

Phase II study of interferon gamma in malignant carcinoid tumors (E9292): a trial of the Eastern Cooperative Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27675

Sunitinib malate for the treatment of pancreatic neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27675

Everolimus for advanced pancreatic neuroendocrine tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27675

Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27675

The North American Neuroendocrine Tumor Society consensus guideline for the diagnosis and management of neuroendocrine tumors: pheochromocytoma, paraganglioma, and medullary thyroid cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27675

Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27675

Novel and evolving therapies in the treatment of malignant phaeochromocytoma: experience with the mTOR inhibitor everolimus (RAD001).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27675

Malignant pheochromocytomas and paragangliomas: molecular signaling pathways and emerging therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27675

Sunitinib, a novel therapy for anthracycline- and cisplatin-refractory malignant pheochromocytoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27675

Use of the tyrosine kinase inhibitor sunitinib in a patient with von Hippel-Lindau disease: targeting angiogenic factors in pheochromocytoma and other von Hippel-Lindau disease-related tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27675

Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27675

FDG uptake is a surrogate marker for defining the optimal biological dose of the mTOR inhibitor everolimus in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27675

Downregulation of 18F-FDG uptake in PET as an early pharmacodynamic effect in treatment of non-small cell lung cancer with the mTOR inhibitor everolimus

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27675

Sunitinib for Asian patients with advanced renal cell carcinoma: a comparable efficacy with different toxicity profiles.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27675

Multicenter phase II study of everolimus in patients with previously treated metastatic gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27675

21 January 2018

Identifiers

DOI

10.1002/CNCR.27675

1 reference

release_5faw7staxbbrjldupb5dh3lo6m

26 July 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/5faw7staxbbrjldupb5dh3lo6m

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference